nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.03.2004 | Original Paper

Lack of neuroprotection by an ACTH (4–9) analogue. A randomized trial in patients treated with vincristine for Hodgkin’s or non-Hodgkin’s lymphoma

verfasst von: S. Koeppen, C. C. P. Verstappen, R. Körte, M. E. Scheulen, D. Strumberg, T. J. Postma, J. J. Heimans, P. C. Huijgens, B. Kiburg, K. Renzing-Köhler, H. C. Diener

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 3/2004

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This randomized, double-blind, placebo-controlled study evaluates the effect of the corticotropin (4–9) analogue Org 2766 on the neuropathy-free interval in patients receiving vincristine (VCR) containing chemotherapy for Hodgkin’s or non-Hodgkin’s lymphoma.

Patients and methods

In a longitudinal design, 150 patients were evaluated by interview, neurological examination, and neurophysiological techniques. Patients with an expected cumulative VCR dose of at least 8 mg received a single dose of Org 2766 or placebo before and after each intravenous VCR injection and 3–4 weeks after cessation of VCR. The final patient assessment was performed 1 month after discontinuation of study medication. The neuropathy-free interval as the major end point of this study was defined as the first occurrence of bilateral paresthesias and expressed as the administered cumulative VCR dose. This bi-center study represents the largest cohort of patients monitored for the effect of an ACTH-analogue on VCR neurotoxicity.

Results

A total of 147 patients were included in the final analysis. No significant differences were observed between the placebo and actively treated group for the major and secondary endpoints.

Conclusion

Contrary to a single previous pilot study in patients receiving VCR-based chemotherapy, in our study the ACTH (4–9) analogue Org 2766 did not provide protection from VCR-induced neuropathy.

Boyle FM, Wheeler HR, Shenfield GM (1996) Glutamate ameliorates experimental vincristine neuropathy. J Pharmacol Exp Ther 279:410–415

Casey EB, Jellife AM, Le Quesne PM, Millett YL (1973) Vincristine neuropathy: clinical and electrophysiological observations. Brain 96:69–86

Contreras PC, Vaught JL, Gruner JA, Brosnan C, Steffler C, Arezzo JC, Lewis ME, Kessler JA, Apfel SC (1997) Insulin-like growth factor-I prevents development of a vincristine neuropathy in mice. Brain Res 774:20–26CrossRefPubMed

Critchley EMR (1987) Neuropathies due to drugs. In: Matthews WB (ed) Neuropathies. In: Vinken PJ, Bruyn GW, Klawans HL (eds) Handbook of clinical neurology, vol. 7, 51. Elsevier Science, Amsterdam, The Netherlands, pp 293–314

Dambska M, Muzylak M, Maslinska D (1995) The features of peripheral nerve lesions in young and adult rabbits after vincristine administration. Folia Neuropathol 33:21–24PubMed

De Koning P, Gispen WH (1987a) ORG 2766 improves functional and electrophysiological aspects of regenerating sciatic nerve in the rat. Peptides 8:415–422PubMed

De Koning P, Neijt JP, Jennekens FGI, Gispen WH (1987b) ORG 2766 protects from cisplatin-induced neurotoxicity in rats. Exp Neurol 97:746–750PubMed

De Koning P, Verhaagen J, Sloot W, Jennekens FGI, Gispen WH (1989) ORG 2766 stimulates collateral sprouting in the soleus muscle of the rat following partial denervation. Muscle Nerve 12:353–359PubMed

Duckers HJ, Verhaagen J, Gispen WH (1993) The neurotrophic analogue of ACTH (4–9), ORG 2766, protects against experimental allergic neuritis. Brain 116:1059–1075PubMed

Duckers HJ, Verhaagen J, de Bruijn E, Gispen WH (1994) Effective use of a neurotrophic ACTH 4–9 analogue in the treatment of a peripheral demyelinating syndrome (experimental allergic neuritis): an intervention study. Brain 117:365–374PubMed

Favaro G, di Gregorio F, Panozzo C, Fiori MG (1988) Ganglioside treatment of vincristine-induced neuropathy. An electrophysiologic study. Toxicology 49:325–329CrossRefPubMed

Gerritsen van der Hoop R, De Koning P, Boven E, Neijt JP, Jennekens FGI, Gispen WH (1988) Efficacy of the neuropeptide ORG 2766 in the prevention and treatment of cisplatin-induced neurotoxicity in rats. Eur J Cancer Clin Oncol 24:637–642PubMed

Gerritsen van der Hoop R, Vecht CJ, van der Burg MEL, Elderson A, Boogerd W, Heimans JJ, Vries EP, van Houwelingen JC, Jennekens FGI, Gispen WH, Neijt JP (1990) Prevention of cisplatin neurotoxicity with an ACTH (4–9) analogue in patients with ovarian cancer. N Engl J Med 322:89–94PubMed

Gerritsen van der Hoop R, Hamers FPT, Neijt JP, Veldman H, Gispen WH, Jennekens FGI (1994) Protection against cisplatin-induced neurotoxicity by ORG 2766: Histological and electrophysiological evidence. J Neurol Sci 126:109–115CrossRefPubMed

Gispen WH (1993) The potential of melanotropins in the treatment of nervous system diseases. Ann NY Acad Sci 31:401–411

Gispen WH, Adan RA (1999) Melanocortins and the treatment of nervous system disease. Potential relevance to the skin? Ann NY Acad Sci 885:342–349PubMed

Goldberg JM, Lindblom U (1979) Standardised method of determining vibratory perception thresholds for diagnosis and screening in neurological investigation. J Neurol Neurosurg Psychiatry 42:793–803PubMed

Gottschalk PG, Dyck PJ, Kiely JM (1968) Vinca alkaloid neuropathy: nerve biopsy studies in rats and in man. Neurology 18:875–882PubMed

Hamers FPT, Pette C, Bravenboer B, Vecht CJ, Neijt JP, Gispen WH (1993) Cisplatin-induced neuropathy in mature rats: effects of the melanocortin-derived peptide ORG 2766. Cancer Chemother Pharmacol 32:162–166PubMed

Hayakawa K, Itoh T, Niwa H, Mutoh T, Sobue G (1998) NGF prevention of neurotoxicity induced by cisplatin, vincristine and taxol depends on toxicity of each drug und NGF treatment schedule: in vitro study of adult rat sympathetic ganglion explants. Brain Res 794:313–319CrossRefPubMed

Holland JF, Scharlau C, Gailani S, Krant MJ, Olson KB, Horton J, Shnider BI, Lynch JJ, Owens A, Carbone PP, Colsky J, Grob D, Miller SP, Hall TC (1973) Vincristine treatment of advanced cancer: a cooperative study of 392 cases. Cancer Res 33:1258–1264PubMed

Hovestadt A, van der Burg MEL, Verbiest HBC, van Putten WLJ, Vecht CJ (1992) The course of neuropathy after cessation of cisplatin treatment, combined with ORG 2766 or placebo. J Neurol 239:143–146PubMed

Kiburg B, van de Loosdrecht AA, Schweitzer KM, Ossenkoppele GJ, Müller LJ, Heimans JJ, Huijgens PC (1994) Effects of the ACTH (4–9) analogue, ORG 2766, on vincristine cytotoxicity in two human lymphoma cell lines, U 937 and U 715. Br J Cancer 69:497-501PubMed

Kiburg B, Moorer-van Delft C, Heimans JJ, Huijgens PC, Boer HH (1996) In vivo modulation of vincristine-induced neurotoxicity in Lymnaea stagnalis, by the ACTH (4–9) analogue Org 2766. J Neuro-Oncol 30:173–180

Legha SS (1986) Vincristine neurotoxicity: pathophysiology and management. Med Toxicol 1:421–427PubMed

Links M, Lewis C (1999) Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy. Drugs 57:293–308CrossRefPubMed

Müller LJ, Moorer-van Delft CM, Boer HH (1992) The ACTH/MSH (4–9) analogue ORG 2766 stimulates microtubule formation in axons of central neurons of the snail Lymnaea stagnalis. Peptides 13:769–774CrossRefPubMed

Nowrousian MR, Ernst S, Beling C, Fink H, Welt A, Schuette J, Moritz T, Flasshove M, Bojko P, Seeber S, Metz KA, Stuschke M (2001) CEBOPP/VIML followed by radiotherapy for unfavorable early-stage or advanced-stage Hodgkin’s disease. Blood 98:131a

Pal PK (1999) Clinical and electrophysiological studies in vincristine induced neuropathy. Electromyogr Clin Neurophysiol 39:323–330PubMed

Postma TJ, Benard BA, Huijgens PC, Ossenkoppele GJ, Heimans JJ (1993) Long term effects of vincristine on the peripheral nervous system. J Neuro-Oncol 15:23–27

Postma TJ, Heimans JJ (2000) Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol 11:509–513CrossRefPubMed

Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral neuropathy. J Neurol 249:9–17PubMed

Roberts JA, Jenison EL, Kim KM, Clarke-Pearson D, Langleben A (1997) A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecol Oncol 67:172–177CrossRefPubMed

Rosenthal S, Kaufman S (1974) Vincristine neurotoxicity. Ann Intern Med 80:733–737PubMed

Russell JW, Windebank AJ, McNiven MA, Brat DJ, Brimijoin WS (1995) Effect of cisplatin and ACTH (4–9) on neural transport in cisplatin induced neurotoxicity. Brain Res 676:258–267CrossRefPubMed

Sahenk Z, Brady ST, Mendell JR (1987) Studies on the pathogenesis of vincristine-induced neuropathy. Muscle Nerve 10:80–84PubMed

Sandler SG, Tobin W, Henderson ES (1969) Vincristine-induced neuropathy: a clinical study of fifty leukemic patients. Neurology 19:367–374PubMed

Stengs CH, Klis SF, Huizing EH, Smoorenburg GF (1998) Protective effects of a neurotrophic ACTH (4–9) analog on cisplatin ototoxicity in relation to the cisplatin dose: an electrocochleographic study in albino guinea pigs. Hear Res 124:108–117CrossRefPubMed

Strand FL, Kung TT (1980) ACTH accelerates recovery of neuromuscular function following crushing of peripheral nerve. Peptides 1:135–138CrossRefPubMed

Strand FL (2000) David and Goliath – the slingshot that started the neuropeptide revolution. Eur J Pharmacol 405:3–12CrossRefPubMed

Topp KS, Tanner KD, Levine JD (2000) Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat. J Comp Neurol 424:563–576CrossRefPubMed

Tuxen MK, Hansen SW (1994) Neurotoxicity secondary to antineoplastic drugs. Cancer Treat Rev 20:191–214PubMed

Van der Zee CEEM, Gerritsen van der Hoop R, Gispen WH (1989) Beneficial effect of ORG 2766 in treatment of peripheral neuropathy in streptozocin-induced diabetic rats. Diabetes 38:225–230PubMed

Van Gerven JMA, Hovestadt A, Moll JWB, Rodenburg CJ, Splinter TAW, van Oosterom AT, Keizer L, Drogendijk TE, Groenhout CM, Vecht CJ, Neijt JP (1994) The effects of an ACTH (4–9) analogue on development of cisplatin neuropathy in testicular cancer: A randomized trial. J Neurol 241:432–435PubMed

Van Kooten B, van Diemen HAM, Groenhout KM, Huijgens PC, Ossenkoppele GJ, Nauta JJP, Heimans JJ (1992) A pilot study on the influence of a corticotropin (4–9) analogue on vinca-alkaloid-induced neuropathy. Arch Neurol 49:1027–1031PubMed

Van Rijzingen IM, Gispen WH, Spruijt BM (1996)The ACTH (4–9) analog ORG 2766 and recovery after brain damage in animal models – a review. Behav Brain Res. 74:1–15

Verhaagen J, Edwards PM, Jennekens FGI, Gispen WH (1987) Pharmacological aspects of the influence of melanocortins on the formation of regenerative peripheral nerve sprouts. Peptides 8:581–584CrossRefPubMed

Windebank AJ, Smith AG, Russel JW(1994) The effect of nerve growth factor, ciliary neurotrophic factor, and ACTH analogs on cisplatin neurotoxicity in vitro. Neurology 44:488–494PubMed

Titel: Lack of neuroprotection by an ACTH (4–9) analogue. A randomized trial in patients treated with vincristine for Hodgkin’s or non-Hodgkin’s lymphoma
verfasst von: S. Koeppen
C. C. P. Verstappen
R. Körte
M. E. Scheulen
D. Strumberg
T. J. Postma
J. J. Heimans
P. C. Huijgens
B. Kiburg
K. Renzing-Köhler
H. C. Diener
Publikationsdatum: 01.03.2004
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 3/2004
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-003-0524-9

Neu im Fachgebiet Onkologie

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

ASS schützt nicht vor Brustkrebsrezidiven

02.05.2024 Mammakarzinom Nachrichten

Nützt nichts und ist vielleicht sogar schädlich: In einer Phase-3-Studie konnten täglich 300 mg ASS keine Brustkrebsrezidive bei Frauen vermeiden, die ein hohes Risiko für eine Tumorrückkehr aufwiesen. Tendenziell traten unter ASS sogar häufiger Rezidive auf als unter Placebo.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Bildnachweise

Frau nutzt Gehhilfe /© Photographee.eu / Fotolia (Symbolbild mit Fotomodellen), Darstellung der Dosisverteilung bei Bestrahlung eines Prostatakarzinoms/© Degener, S et al. / all rights reserved Springer Medizin Verlag GmbH, Frau mit Tablette und Wasserglas in Händen/© fizkes / stock.adobe.com (Symbolbild mit Fotomodell), Ärztin und künstliche Intelligenz sehen sich Befunde an/© Alexander Limbach / Zoonar/picture alliance (Symbolbild mit Fotomodell)

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Lack of neuroprotection by an ACTH (4–9) analogue. A randomized trial in patients treated with vincristine for Hodgkin’s or non-Hodgkin’s lymphoma